Zyflamend is a dietary supplement that contains extracts of rosemary, turmeric, ginger, holy basil, green tea, hu zhang, Chinese goldthread, barberry, oregano, and Baikal skullcap.
The individual components of Zyflamend have anti-inflammatory and possible anticarcinogenic properties.
In various preclinical studies, Zyflamend has been shown to suppress the expression of certain genes involved in the inflammatory response and in cancer progression, such as cyclooxygenase 1(COX-1), COX-2, 5-lipoxygenase (5-LOX), and 12-LOX.
In other preclinical studies, Zyflamend has demonstrated single-agent anticancer activity and the capacity to be used with hormonal and chemotherapy agents for improved cancer suppression.
Results of a phase I study of Zyflamend suggest that use of this supplement is not associated with serious toxicity or adverse effects.
Prostate cancer affects mainly older men. Four out of five cases are diagnosed in men over 65, but less than 1% in men under 50. Though uncommon, prostate cancer can be seen in men even in their 30's and 40's. Men with a family history of prostate cancer are more likely to develop prostate cancer than the general population.
On a case-by-case basis, doctors cannot say with certainty what causes prostatecancer, but experts generally agree that diet contributes to the risk. Men who consume large...
Zyflamend is a dietary supplement that contains extracts of rosemary (Rosmarinus officinalis L.), turmeric (Curcuma longa L.), ginger (Zingiber officinale Roscoe), holy basil (Ocimum sanctum L.), green tea (Camellia sinensis[L.] Kuntze), hu zhang (Polygonum cuspidatum Siebold & Zucc., a source of resveratrol), Chinese goldthread (Coptis chinensis Franch.), barberry (Berberis vulgaris L.), oregano (Origanum vulgare L.), and Baikal skullcap (Scutellaria baicalensis Georgi). The individual components of Zyflamend have anti-inflammatory and possible anti-carcinogenic properties. For example, results of a 2011 study suggest that Zyflamend may inhibit the growth of melanoma cells.
The extracts in Zyflamend have been shown to have anti-inflammatory effects via inhibition of cyclooxygenase (COX) activity. COXs are enzymes that convert arachidonic acid into prostaglandins, which are thought to play a role in tumor development and metastasis. One COX enzyme, COX-2, is activated during chronic disease states, such as cancer.
The antitumorigenic mechanisms of action of Zyflamend are unknown, but, according to one study, Zyflamend may suppress activation of nuclear factor-kappa B (NF-kappa B) (a nuclear transcription factor involved in tumorigenesis) and NF-kappa B-regulated gene products.
In vitro studies
In a study reported in 2012, human prostate cancer cells were treated in vitro with Zyflamend. Cells treated with the supplement at concentrations ranging from 0.06 to 0.5 μL /mL exhibited dose-dependent decreases in androgen receptor and prostate-specific antigen (PSA) expression levels, compared with cells treated with the dimethyl sulfoxide vehicle control. Prostate cancer cells that were treated with a combination of Zyflamend (0.06 μL/mL) and bicalutamide (25 μM), an androgen receptor inhibitor, showed reductions in cell growth, PSA expression, and anti-apoptotic protein expression, compared with cells treated with Zyflamend or bicalutamide alone.